Akcea Therapeutics Inc (NASDAQ:AKCA) Stock Holdings Boosted by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC increased its stake in Akcea Therapeutics Inc (NASDAQ:AKCA) by 37.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,730 shares of the company’s stock after purchasing an additional 3,203 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Akcea Therapeutics were worth $275,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of AKCA. Rhumbline Advisers raised its holdings in Akcea Therapeutics by 2.4% during the 1st quarter. Rhumbline Advisers now owns 17,159 shares of the company’s stock worth $486,000 after buying an additional 409 shares during the period. First Trust Advisors LP raised its holdings in Akcea Therapeutics by 0.6% during the 1st quarter. First Trust Advisors LP now owns 74,954 shares of the company’s stock worth $2,123,000 after buying an additional 460 shares during the period. Swiss National Bank raised its holdings in Akcea Therapeutics by 2.5% during the 2nd quarter. Swiss National Bank now owns 33,300 shares of the company’s stock worth $781,000 after buying an additional 800 shares during the period. Northern Trust Corp increased its holdings in shares of Akcea Therapeutics by 0.7% in the 2nd quarter. Northern Trust Corp now owns 198,175 shares of the company’s stock valued at $4,646,000 after purchasing an additional 1,390 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Akcea Therapeutics by 47.6% in the 1st quarter. SG Americas Securities LLC now owns 5,677 shares of the company’s stock valued at $161,000 after purchasing an additional 1,831 shares during the period. 25.39% of the stock is owned by institutional investors and hedge funds.

In related news, President Sarah Boyce sold 1,819 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $23.52, for a total value of $42,782.88. Following the transaction, the president now owns 19,888 shares in the company, valued at $467,765.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.10% of the company’s stock.

A number of equities analysts have recently weighed in on AKCA shares. Zacks Investment Research upgraded Akcea Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Friday, August 9th. ValuEngine downgraded Akcea Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, BMO Capital Markets set a $43.00 target price on Akcea Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $36.00.

Shares of AKCA traded down $0.09 during trading hours on Friday, reaching $20.95. The company’s stock had a trading volume of 129,057 shares, compared to its average volume of 124,222. Akcea Therapeutics Inc has a 1-year low of $18.68 and a 1-year high of $37.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.48 and a quick ratio of 6.32. The company has a 50 day moving average of $21.26 and a two-hundred day moving average of $24.56.

Akcea Therapeutics (NASDAQ:AKCA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Akcea Therapeutics had a negative return on equity of 43.87% and a negative net margin of 65.62%. The firm had revenue of $26.62 million during the quarter, compared to analyst estimates of $25.78 million. During the same quarter in the prior year, the company posted ($0.85) EPS. The company’s quarterly revenue was up 45.3% on a year-over-year basis. Equities research analysts expect that Akcea Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.

See Also: What are the benefits of a portfolio tracker?

Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.